Primary tabs
The list of publications is indicative and may not include all publications.
Nonalcoholic fatty liver disease and statins..
Metabolism. 64(10), 1215-23.
(2015).
Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors..
Curr Med Res Opin. 31(3), 435-8.
(2015).
Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?.
J Hypertens. 33(11), 2185-97.
(2015).
Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention..
Curr Med Res Opin. 31(2), 191-5.
(2015).
Contrast-Induced Nephropathy: An "All or None" Phenomenon?.
Angiology. 66(6), 508-13.
(2015).
Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII..
Curr Vasc Pharmacol. 13(6), 696-8.
(2015).
Cardiovascular Risk in Middle East Populations: A Call to Action..
Angiology. 66(9), 801-2.
(2015).
Hyperuricemia as a risk factor for cardiovascular disease..
Expert Rev Cardiovasc Ther. 13(1), 19-20.
(2015).
High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus..
J Diabetes Complications. 29(1), 142-5.
(2015).
Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?.
Cardiology. 131(3), 186-8.
(2015).
Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy..
Curr Vasc Pharmacol. 13(2), 223-5.
(2015).
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?.
Expert Opin Pharmacother. 16(10), 1449-61.
(2015).
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update..
World J Gastroenterol. 21(22), 6820-34.
(2015).
Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease..
Curr Vasc Pharmacol. 13(3), 366-7.
(2015).
Arterial Stiffness and Emerging Biomarkers: Still a Long Journey to Go..
Angiology. 66(10), 901-3.
(2015).
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome..
World J Gastroenterol. 21(25), 7860-8.
(2015).
The role of statins in the treatment of type 2 diabetes mellitus: an update..
Curr Pharm Des. 20(22), 3665-74.
(2014).
Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit..
Expert Rev Cardiovasc Ther. 12(3), 295-6.
(2014).
Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014).
Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases..
J Crohns Colitis. 8(9), 936-44.
(2014).
Are patients with inflammatory bowel diseases at increased risk for cardiovascular disease?.
Clin Gastroenterol Hepatol. 12(12), 2134-5.
(2014).
High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality?.
Curr Med Chem. 21(25), 2917-26.
(2014).
Metabolic syndrome in clinical practice..
Cardiol J. 21(2), 209.
(2014).
Pages
- « πρώτη
- ‹ προηγούμενη
- …
- 2
- 3
- 4
- 5
- 6
- …
- επόμενη ›
- τελευταία »